Violet Therapeutics
Latest round
- Seed
Last raised
- May 2026
Total raised
- $12M
Investors
- 5
About Violet Therapeutics
Based in the US, Violet Therapeutics, Inc. operates as a biotechnology company that engages in the research and development of drugs for treating diseases of the central nervous system and other neurodegeneration diseases. Founded in 2021 by Mass General Brigham Ventures in collaboration with Francisco J. Quintana and others, and based in Massachusetts, US, Violet Therapeutics, Inc. operates as a biopharmaceutical company that engages in the research and development of cellular therapeutics for the treatment of the central nervous system and other diseases. In May 2026, Violet Therapeutics, Inc. The company works with pharmaceutical and biotechnology organizations to provide cell-to-cell communication mapping technologies and therapeutic discovery programs for central nervous system diseases. The company utilizes proprietary platforms, including its CONNECT and C-to-C Engine technologies, to identify signaling pathways involved in neuroinflammation, neurodegeneration, and synaptic dysfunction. Its lead program targets EphB3, a receptor tyrosine kinase implicated in microglia-astrocyte interactions associated with neurological disorders. Violet’s multidisciplinary team of neuroscientists, biologists, bioinformaticians, and drug discovery specialists develops novel therapeutic candidates for conditions such as Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders. The company’s revenue is generated by advancing proprietary therapeutic programs and drug discovery technologies focused on neurodegenerative diseases. Its business model is supported through biotechnology partnerships, strategic research collaborations, licensing opportunities, and venture-backed platform development activities. Violet develops proprietary intellectual property around cell-to-cell communication mapping and therapeutic targets discovered through its platforms. As programs progress toward clinical development, the company may derive value from licensing agreements, co-development arrangements, and potential commercialization partnerships with pharmaceutical and biotechnology organizations.
Who invested in Violet Therapeutics
5 investors across 2 rounds
See all investors in Violet Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Violet Therapeutics
Who invested in Violet Therapeutics?
Violet Therapeutics has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Violet Therapeutics raised?
Violet Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Violet Therapeutics last raise money?
Violet Therapeutics's most recent round on record is a Seed, in May 2026.
What does Violet Therapeutics do?
Based in the US, Violet Therapeutics, Inc.
Where is Violet Therapeutics headquartered?
Violet Therapeutics is headquartered in Somerville, US.
Which VCs invest in companies like Violet Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Violet Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Violet Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.